MEDIGUS LTD - SPON ADR (MDGS) Fundamental Analysis & Valuation
NASDAQ:MDGS • US58471G4091
Current stock price
2.36 USD
+0.18 (+8.28%)
At close:
2.6 USD
+0.24 (+10.17%)
After Hours:
This MDGS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDGS Profitability Analysis
1.1 Basic Checks
- MDGS had negative earnings in the past year.
- MDGS had a negative operating cash flow in the past year.
1.2 Ratios
- MDGS has a Return On Assets of -15.49%. This is comparable to the rest of the industry: MDGS outperforms 57.95% of its industry peers.
- MDGS has a Return On Equity of -41.78%. This is comparable to the rest of the industry: MDGS outperforms 51.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.49% | ||
| ROE | -41.78% | ||
| ROIC | N/A |
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MDGS's Gross Margin of 14.92% is on the low side compared to the rest of the industry. MDGS is outperformed by 81.03% of its industry peers.
- MDGS's Gross Margin has declined in the last couple of years.
- MDGS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
2. MDGS Health Analysis
2.1 Basic Checks
- MDGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for MDGS has been reduced compared to 1 year ago.
- MDGS has a worse debt/assets ratio than last year.
2.2 Solvency
- MDGS has an Altman-Z score of -0.19. This is a bad value and indicates that MDGS is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of MDGS (-0.19) is comparable to the rest of the industry.
- A Debt/Equity ratio of 0.11 indicates that MDGS is not too dependend on debt financing.
- MDGS's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. MDGS outperforms 55.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.19 |
ROIC/WACCN/A
WACC7.41%
2.3 Liquidity
- MDGS has a Current Ratio of 1.30. This is a normal value and indicates that MDGS is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.30, MDGS is not doing good in the industry: 87.69% of the companies in the same industry are doing better.
- MDGS has a Quick Ratio of 1.23. This is a normal value and indicates that MDGS is financially healthy and should not expect problems in meeting its short term obligations.
- MDGS has a Quick ratio of 1.23. This is in the lower half of the industry: MDGS underperforms 75.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.23 |
3. MDGS Growth Analysis
3.1 Past
- MDGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -116.00%.
- Looking at the last year, MDGS shows a very strong growth in Revenue. The Revenue has grown by 158.35%.
- MDGS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 187.58% yearly.
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. MDGS Valuation Analysis
4.1 Price/Earnings Ratio
- MDGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDGS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. MDGS Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 29.82%, MDGS is a good candidate for dividend investing.
- In the last 3 months the price of MDGS has falen by -30.59%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- MDGS's Dividend Yield is rather good when compared to the industry average which is at 0.24. MDGS pays more dividend than 100.00% of the companies in the same industry.
- MDGS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 29.82% |
5.2 History
- MDGS is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- The earnings of MDGS are negative and hence is the payout ratio. MDGS will probably not be able to sustain this dividend level.
DP-31.57%
EPS Next 2YN/A
EPS Next 3YN/A
MDGS Fundamentals: All Metrics, Ratios and Statistics
2.36
+0.18 (+8.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-23 2022-09-23/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change-99.92%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.47M
Revenue(TTM)110.29M
Net Income(TTM)-13.27M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 29.82% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP-31.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.14 | ||
| P/tB | 6.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.98
EYN/A
EPS(NY)-4.9
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS58.21
BVpS16.77
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.49% | ||
| ROE | -41.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.92% | ||
| FCFM | N/A |
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
F-Score3
Asset Turnover1.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 51.17% | ||
| Cap/Sales | 1.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -0.19 |
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)598.88%
Cap/Depr(5y)379.57%
Cap/Sales(3y)37.08%
Cap/Sales(5y)27.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.17%
OCF growth 3YN/A
OCF growth 5YN/A
MEDIGUS LTD - SPON ADR / MDGS Fundamental Analysis FAQ
What is the fundamental rating for MDGS stock?
ChartMill assigns a fundamental rating of 2 / 10 to MDGS.
Can you provide the valuation status for MEDIGUS LTD - SPON ADR?
ChartMill assigns a valuation rating of 0 / 10 to MEDIGUS LTD - SPON ADR (MDGS). This can be considered as Overvalued.
How profitable is MEDIGUS LTD - SPON ADR (MDGS) stock?
MEDIGUS LTD - SPON ADR (MDGS) has a profitability rating of 1 / 10.
Can you provide the dividend sustainability for MDGS stock?
The dividend rating of MEDIGUS LTD - SPON ADR (MDGS) is 4 / 10 and the dividend payout ratio is -31.57%.